Quidel gains CLIA waiver for RSV test
This article was originally published in Clinica
Executive Summary
The US FDA has granted CLIA waiver status for the QuickVue respiratory syncytial virus (RSV) test developed by Quidel. The diagnostic received FDA 510(k) clearance in 2006 (see Clinica No 1228, p 18), and is now more widely available, as the CLIA waiver means it may be offered in physicians' offices and clinics. The QuickVue product detects RSV from nasopharyngeal swab and nasopharyngeal aspirate specimens. It is intended to aid the diagnosis of acute RSV infections in symptomatic paediatric patients, the San Diego, California-based firm said.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.